Test Price
2,800 AED✅ Home Collection Available
TRAPPC11 Gene Limb‑Girdle Muscular Dystrophy, Autosomal Recessive Type 2S (LGMD‑2S) Genetic Test in UAE | 2,800 AED | DNA Labs UAE
Executive Summary & Core Metrics
Executive Summary & Core Metrics
- Accuracy: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139).
- Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
- Clinical Guidance: Telephonic Post-Test Clinical Guidance by a DHA-licensed Consultant Medical Geneticist.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The TRAPPC11 Gene NGS Test utilizes next‑generation sequencing (NGS) to provide comprehensive coverage of the TRAPPC11 gene. This method identifies single nucleotide variants, insertions, deletions, and copy number variations associated with autosomal recessive limb‑girdle muscular dystrophy type 2S (LGMD‑2S). The assay enables precise diagnosis, prognosis, and family risk stratification.
| Feature | Our TRAPPC11 NGS Test (ISO‑Lab) | Closest Alternative (Standard Genetic Screening) |
|---|---|---|
| Methodology | Next‑Generation Sequencing (NGS) – full gene coverage | Sanger sequencing of selected exons or targeted panel |
| Diagnostic Precision | 99.9% analytical sensitivity & >99% specificity | Variable; may miss deep intronic or copy‑number variants |
| Turnaround Time | 3–4 Weeks | 4–8 Weeks |
| Sample Type | Whole Blood, DNA FTA Card, or Extracted DNA | Whole Blood only |
Physician Insight & Safety Protocols
Lina Osama Zaki Quteineh | Consultant Medical Genetics | DHA Registration ID: 9294403: “This NGS-based test provides critical insight into LGMD‑2S, a rare progressive muscle disorder. A genetic finding must always be correlated with the clinical presentation, electromyography, and muscle biopsy results. I strongly encourage families to pair the result with comprehensive genetic counselling to fully understand the inheritance pattern and implications for family planning. A negative result does not exclude other limb‑girdle dystrophies.”
Medication & Management Advisory
Exclusion Criteria & Emergency Red Flags
- Acute febrile illness or systemic infection within 48 hours before sample collection.
- Known haematological malignancy requiring urgent specialist clearance.
- Severe cutaneous condition at venipuncture site or extreme needle phobia (contact lab for alternative collection).
- ER Red Flags: Sudden worsening muscle weakness, difficulty breathing or swallowing, dark cola‑coloured urine (rhabdomyolysis), or unexplained falls – seek emergency care immediately.
Patient FAQ & Clinical Guidance
1. What is the purpose of the TRAPPC11 gene test?
This test detects disease‑causing variants in the TRAPPC11 gene to confirm autosomal recessive limb‑girdle muscular dystrophy type 2S (LGMD‑2S). It aids in precise diagnosis, prognosis, and family risk stratification.
2. How is the sample collected and what preparation is needed?
A simple blood draw via VIP mobile phlebotomy or a DNA FTA card sample is required. No fasting or medication discontinuation is necessary.
3. How should I interpret the result and what are the next steps?
A positive result confirms the genetic basis of LGMD‑2S. A follow‑up with a clinical geneticist or neurologist is essential for management and family counselling.
UAE Regulatory & Data Privacy Adherence
Our Commitment to Compliance
- Licensed by DHA/MOHAP – Facility License: 1143
- ISO 9001:2015 Certified (Cert: INT/EGQ/2509DA/3139)
- Data Privacy: Fully compliant with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
- Patient Safety & Consent: Adheres to Federal Decree‑Law No. 4 of 2016 on Medical Liability.
Clinical & Logistical Metadata
| Test Name | TRAPPC11 Gene Limb‑Girdle Muscular Dystrophy, Autosomal Recessive Type 2S (LGMD‑2S) Genetic Test |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Whole Blood, DNA FTA Card, or Extracted DNA |
| Methodology Used | Next‑Generation Sequencing (NGS) – full gene coverage |
| ICD-10-CM Code | G71.0 (Muscular dystrophy) |
| LOINC Code | 81247-9 (Muscular dystrophy panel) |
| DHA Facility License & Address | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | License No. 1143 |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians